http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021095400-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51fb8da13cf5905797ba131d3f9c92e8 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 |
| filingDate | 2020-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1b5e71b8eb2a97fd7ae756300ac49e6 |
| publicationDate | 2021-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2021095400-A |
| titleOfInvention | MRI contrast agent composition |
| abstract | PROBLEM TO BE SOLVED: To provide an MRI contrast agent composition which facilitates uptake of a contained MRI contrast agent into cancer cells. The MRI contrast agent composition of the present invention contains a monosaccharide and an MRI contrast agent, and the monosaccharide is not covalently bound to another molecule. The MRI contrast agent composition may contain the MRI contrast agent and the monosaccharide in a mass ratio of 1: 0.01 to 1: 100. The MRI contrast agent may be a gadolinium contrast agent, and the monosaccharide may be glucose. [Selection diagram] Fig. 5 |
| priorityDate | 2019-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.